



US009636415B2

(12) **United States Patent**
Mudde et al.

(10) **Patent No.:** US 9,636,415 B2
(45) **Date of Patent:** *May 2, 2017

(54) **BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES**

(71) Applicant: S-TARGET therapeutics GmbH, Vienna (AT)

(72) Inventors: Geert Mudde, Vienna (AT); Gottfried Himmller, Vienna (AT)

(73) Assignee: S-TARGET THERAPEUTICS GMBH, Vienna (AT)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: 13/791,824

(22) Filed: Mar. 8, 2013

(65) **Prior Publication Data**

US 2013/0243767 A1 Sep. 19, 2013

Related U.S. Application Data

(63) Continuation-in-part of application No. 12/281,504, filed as application No. PCT/EP2007/001722 on Feb. 28, 2007, now abandoned.

(30) **Foreign Application Priority Data**

Mar. 3, 2006 (EP) 06110672

(51) **Int. Cl.**

A61K 38/00 (2006.01)
A61K 48/00 (2006.01)
A61K 39/00 (2006.01)
A61K 39/385 (2006.01)
A61K 47/48 (2006.01)
C07K 14/47 (2006.01)
C07K 16/28 (2006.01)
A61K 39/35 (2006.01)
A61K 39/39 (2006.01)

(52) **U.S. Cl.**

CPC *A61K 47/48369* (2013.01); *A61K 39/0008* (2013.01); *A61K 39/0011* (2013.01); *A61K 39/35* (2013.01); *A61K 39/385* (2013.01); *A61K 39/39* (2013.01); *C07K 14/4713* (2013.01); *C07K 14/4748* (2013.01); *C07K 16/28* (2013.01); *C07K 16/283* (2013.01); *C07K 16/2896* (2013.01); *A61K 2039/55561* (2013.01); *A61K 2039/6056* (2013.01); *C07K 2317/34* (2013.01); *C07K 2317/526* (2013.01); *C07K 2317/55* (2013.01); *C07K 2317/622* (2013.01); *C07K 2317/64* (2013.01); *C07K 2318/20* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56)

References Cited

FOREIGN PATENT DOCUMENTS

EP	0 178 085	4/1986
EP	0 287 361	10/1988
EP	0640130	3/1995
WO	WO/97/07218	2/1997
WO	WO/03/035695	5/2003
WO	PCT/EP2006/050059	7/2006

OTHER PUBLICATIONS

Ngo et al. 'Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox'. *The Protein Folding Problem and Tertiary Structure Prediction*. Ed. K. Merz and S. Le Grand. Boston: Birkhauser, 1994.491-495.*

Skolnick et al. 'From genes to protein structure and function: novel applications of computational approaches in the genomic era.' *Trends in Biotech.* 18:34-39, 2000.*

Attwood et al. 'The Babel of Bioinformatics.' *Science*. 290(5491):471-473.*

Blumenthal et al. 'Definition of an Allergen.' *Allergens and Allergen Immunotherapy*. Ed. R Lockey, S. Bunkatz and J. Bousquet. New York: Marcel Decker, 2004.37-50.*

Means et al. 'Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.' *J. Clin. Invest.* 115(2):402-417, 2005.*

Davies et al. 'Immune complex processing in patients with systemic lupus erythematosus.' *j. Clin. Invest.* 90:2075=2083, 1992.*

Barton G M et al., "Intracellular localization of toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA," *Nat Immunol*, Jan. 2006;7(1):49-56.

Baselmans P J et al., 2000, *Hum Immunol* 61:789-798.

Beck H et al., 2001, *Eur J Immunol* 31:3726-3736.

Bheekha Escura R- et al., *Immunology*, 1995, 86:343-350.

Bian H et al., 2003, *Methods* 29:299-309.

Bjersing JL et al., 2005, *Immunobiology*, vol. 210, No. 1, pp. 23-32.

Charbonnier A S, 2003, *J Leukocate Biol*, 73:91-99.

Chen W L et al., 2005, *Immunol Lett*, 98:153-159.

Chua K Y et al., 1991, *Clin Exp Allergy*, 21:161-166.

Eaton-Bassiri A et al., 2004, *Infect Immun*, 72:7202-7211.

Ebner C 1999, *Int Arch Allergy Immunol*, 119:1-5.

Ferreira F et al., 1998, *FASEB Journal*, 12:231-242.

Higgins J A et al., 1994, *J Allergy Clin Immunol*, 93:891-899.

Horejs-Hoeck J et al., 2005, *Immunology*, vol. 115, No. 3, pp. 407-415.

Kapsenberg M L et al., 1999, *Clin Exp Allergy*, 29:33-36.

Latz E et al., 2004, *Nat Immunol*, 5:190-198.

Le Gall F et al., 2004, *J Immunol Methods*, 285:111-127.

Leifer C A et al., 2004, *J Immunol*, 173:1179-1183.

Leroy B P et al., 1992, *Dermatology*, 184:271-274.

Mudde G C et al., *Immunol Cell Biol*, 1996, 74:167-173.

Orlandi R et al., 1989, *Proc Natl Acad Sci*, 86:3833-3837.

Péne 1988, *J. Proc Natl Acad Sci*, 85:6880-6884.

Rissoan M C, et al., 1999, *Science*, 283:1183-1186.

Rothenfusser S et al., 2002, *Hum Immunol*, 63:1111-1119.

Schuster M P Umana, et al., 2005, *Cancer Res*, 65:7934-7941.

Sturniolo T et al., 2003, *Nat Biotechnol*, 17:555-561.

(Continued)

Primary Examiner — Nora Rooney

(74) *Attorney, Agent, or Firm* — Loza & Loza, LLP;
Michael F. Fedrick

(57) **ABSTRACT**

A molecule or molecule complex capable of binding to TLR9 and to CD32 comprising at least one epitope of at least one antigen, and its use as a medicament for the treatment of allergies.